Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: William Welch, Dirk van den Boom, Ron Lindsay, Frederic Walder

Premium

Sequenom has promoted several members of its management team. William Welch is now the president and chief operating officer. He was previously senior vice president of diagnostics and has overseen the commercial operations of the MaterniT21 Plus test. Dirk van den Boom has been appointed executive vice president of research and development and chief technology officer from his position of senior vice president of research and development, which he has held since 2010. He joined the company in 1998. Ron Lindsay is now executive vice president of strategic planning. He was previously the executive vice president of research and development.


Fluidigm has named Frederic Walder to serve as its chief operating officer. Walder has been chief business officer at Fluidigm since 2010. From 1992 to 2010, Walder held various senior executive posts at Thermo Fisher Scientific.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.